ALXN1210-MG-306: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis

Grants and Contracts Details

StatusFinished
Effective start/end date12/20/1911/13/20

Funding

  • Syneos Health LLC: $11,825.00